Erasca, Inc. (ERAS) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$46.9M; Operating income (m); Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA -$187.19M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$31.86M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$33.79M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2020-06-30 to 2026-06-30
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$46.9M | (m) | (m) | (m) | (m) | $8.00K* | -$27.27M* | (m) | (m) | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$187.19M | (m) | (m) | (m) | (m) | $36.00K | -$27.38M | (m) | (m) | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$31.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$33.79M | (m) | (m) | (m) | (m) | $6.00K* | -$21.66M* | (m) | (m) | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$37.34M | (m) | (m) | (m) | (m) | $30.00K* | -$20.53M* | (m) | (m) | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$34.81M | (m) | (m) | (m) | (m) | $83.00K | -$31.55M | (m) | (m) | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$34.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$36.4M | (m) | (m) | (m) | (m) | $5.00K* | -$22.42M* | (m) | (m) | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$66.68M | (m) | (m) | (m) | (m) | $13.00K* | -$29.18M* | (m) | (m) | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$37.85M | (m) | (m) | (m) | (m) | $42.00K | -$33.25M | (m) | (m) | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$32.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$33.72M | (m) | (m) | (m) | (m) | $240.00K* | -$24.12M* | (m) | (m) | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$35.02M | (m) | (m) | (m) | (m) | $247.00K* | -$25.95M* | (m) | (m) | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$36.13M | (m) | (m) | (m) | (m) | $1.21M | -$26.36M | (m) | (m) | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$137.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$36.19M | (m) | (m) | (m) | (m) | $1.79M* | -$23.95M* | (m) | (m) | (m) | (m) |
|---|
| 2022-06-30 | Reported | -$35.37M | (m) | (m) | (m) | (m) | $4.56M* | -$27.14M* | (m) | (m) | (m) | (m) |
|---|
| 2022-03-31 | Reported | -$36.1M | (m) | (m) | (m) | (m) | $7.34M | -$25.81M | (m) | (m) | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$30.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$45.85M | (m) | (m) | (m) | (m) | $4.67M* | -$23.22M* | (m) | (m) | (m) | (m) |
|---|
| 2021-06-30 | Reported | -$28.02M | (m) | (m) | (m) | (m) | $579.00K* | -$18.23M* | (m) | (m) | (m) | (m) |
|---|
| 2021-03-31 | Reported | -$19.46M | (m) | (m) | (m) | (m) | $122.00K | -$15.67M | (m) | (m) | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$66.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$11.02M | (m) | (m) | (m) | (m) | $149.00K* | -$7.48M* | (m) | (m) | (m) | (m) |
|---|
| 2020-06-30 | Reported | -$7.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$137.8M | (m) | (m) | (m) | (m) | $128.00K | -$95.45M | (m) | (m) | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$175.78M | (m) | (m) | (m) | (m) | $60.00K | -$109.42M | (m) | (m) | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$137.79M | (m) | (m) | (m) | (m) | $1.77M | -$101.22M | (m) | (m) | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$244.81M | (m) | (m) | (m) | (m) | $14.55M | -$103.26M | (m) | (m) | (m) | (m) |
|---|
| 2021-12-31 | Reported | -$124.05M | (m) | (m) | (m) | (m) | $11.21M | -$79.60M | (m) | (m) | (m) | (m) |
|---|
| 2020-12-31 | Reported | -$108.71M | (m) | (m) | (m) | (m) | $947.00K | -$32.69M | (m) | (m) | (m) | (m) |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|